BioTech IP Review

Assignee: Guardant Health, Inc.
Patent Number: 12,286,672
Issued: April 29, 2025 (publication reported June 9, 2025)
Inventors: AmirAli Talasaz, Helmy Eltoukhy, Stefanie Ann Ward Mortimer
Category: Biotechnology / Genomic analysis

What the Patent Covers

This patent protects proprietary methods and systems for detecting genetic variants — especially copy number variations and other genomic alterations — in DNA samples. The invention broadly covers the following (based on typical USPTO abstracts of this class of patents):

• Tagging double‑stranded polynucleotides (DNA fragments) with unique duplex tags.
• Sequencing these tagged DNA molecules from a sample (e.g., circulating tumor DNA in blood).
• Bioinformatically analyzing the sequencing data to determine genetic variants, including copy number changes.
• Using the resulting variant information to inform clinical decision‑making, such as cancer detection or treatment selection.

In essence, the patent strengthens Guardant’s core measurement technology that enables highly sensitive liquid biopsy tests by improving detection accuracy of genomic changes from complex blood samples — the foundational mechanism underlying many of Guardant’s tests.

---

Why This Patent Is Important

• Strategic core technology: Detecting genetic variants (including copy number variation) is central to Guardant’s liquid biopsy products like Guardant360®, Reveal®, and emerging early‑detection platforms — all of which rely on measuring DNA alterations from blood samples.
• Commercial leverage: Exclusive rights to methods that improve variant detection enhance Guardant’s competitive moat and support its market leadership in precision oncology diagnostics.
• Litigation relevance: Guardant and competitors repeatedly litigate around variant‑detection patent families, underscoring the commercial value of these rights in the multi‑billion‑dollar liquid biopsy market.